Company / Depreciation & Amortization
MADRIGAL PHARMACEUTICALS, INC. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$1.5M
FY2025
5-year range
$405.0K / $1.5M
FY2021-FY2025
Trend
+37.4%
vs FY2024
Sector context
#111 of 168
Health Care
What the data says
At $2M, MADRIGAL PHARMACEUTICALS, INC.'s depreciation & amortization ranks #58 of 168 in the Health Care sector. Depreciation & Amortization has increased for 4 consecutive years, from $405,000 in FY2021 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +26.2%.
Increased from $527,000 to $2M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +47.7%
- 5-Year CAGR
- +26.2%
- 10-Year CAGR
- -
Sector benchmark
#58 of 168 in Health CareTop 34% of 168This company $1.5M Sector average $212.9M
▼
-99.3% below sector average
Key checks
Key Insights
- MADRIGAL PHARMACEUTICALS, INC.'s depreciation & amortization has grown for 4 consecutive years.
- 5-year CAGR of +26.2%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 37.4% year-over-year.
- Ranks #111 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.5M | +37.4% |
| FY2024 | $1.1M | +108.0% |
| FY2023 | $527.0K | +12.8% |
| FY2022 | $467.0K | +15.3% |
| FY2021 | $405.0K | -14.0% |
| FY2020 | $471.0K | +320.5% |
| FY2019 | $112.0K | +16.7% |
| FY2018 | $96.0K | +24.7% |
| FY2017 | $77.0K | +49259.0% |
| FY2016 | $156 | -100.0% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026